Pfizer checks if migraine drug versions match up
NCT ID NCT07261371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested four different formulations of a CGRP receptor antagonist, a drug used for migraines, in 64 healthy adults. The goal was to see if the different versions are absorbed and processed by the body in the same way. This is a Phase 1 trial, so it focuses on safety and how the drug behaves, not on treating a condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- calcitonin gene-related peptide receptor inhibitor
- What this could lead to
- If successful, this could help ensure that different versions of this migraine medication are equally effective and safe.
- What could go wrong
- This is an early Phase 1 study in healthy volunteers, not patients. It only checks how the drug is processed, not whether it works for migraines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?